Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1NFX

CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944

Summary for 1NFX
Entry DOI10.2210/pdb1nfx/pdb
Related1EZQ 1F0R 1F0S 1NFU 1NFW 1NFY
DescriptorCOAGULATION FACTOR XA, heavy chain, Coagulation factor XA, light chain, CALCIUM ION, ... (5 entities in total)
Functional Keywordshydrolase
Biological sourceHomo sapiens (human)
More
Cellular locationSecreted: P00742 P00742
Total number of polymer chains2
Total formula weight44306.48
Authors
Maignan, S.,Guilloteau, J.P. (deposition date: 2002-12-16, release date: 2003-02-25, Last modification date: 2024-10-30)
Primary citationMaignan, S.,Guilloteau, J.P.,Choi-Sledeski, Y.M.,Becker, M.R.,Ewing, W.R.,Pauls, H.W.,Spada, A.P.,Mikol, V.
Molecular structures of human Factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.
J.Med.Chem., 46:685-690, 2003
Cited by
PubMed Abstract: The structures of the noncovalent complex of human factor Xa (fXa) with four non-peptide inhibitors containing a central sulfonylpiperazinone scaffold have been determined to about 2.1 A resolution. Highly potent fXa inhibitors containing both neutral groups such as chlorobenzothiophene or chlorothiophene and basic groups such as benzamidine were shown to interact in the S1 pocket through the neutral group whereas the S4 pocket is occupied by the basic moiety. The scaffold comprising the sulfonyl keto piperazine moiety might play a pivotal role in the orientation of substituents, since there is a strong hydrogen bond between Gly219 of fXa and the carbonyl oxygen of the piperazine. This unique "reverse" binding mode is heretofore unreported in fXa and shows that electrostatic interactions in the S1 subsite are not an absolute requirement to maintain high affinity. Selectivity against other serine proteases can be readily explained in light of these structural results. It has opened up new prospects for designing fXa inhibitors with increased oral bioavailability.
PubMed: 12593649
DOI: 10.1021/jm0203837
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.15 Å)
Structure validation

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon